Table 2.
Effect of the homozygous Q222R DNase 1 SNP on cardiovascular and all-cause mortality of STEMI patients at long-term follow-up
| Factor | Cardiovascular mortality | All-cause mortality | ||||
|---|---|---|---|---|---|---|
| Adjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |
| Age | 1.09 | 1.06–1.12 | < 0.0001 | 1.07 | 1.05–1.09 | < 0.0001 |
| Male sex | 0.99 | 0.56–1.77 | 0.975 | 1.29 | 0.84–1.99 | 0.246 |
| BMI | 1.02 | 0.97–1.08 | 0.440 | 0.99 | 0.94–1.03 | 0.531 |
| Hyperlipidemia | 0.73 | 0.43–1.25 | 0.248 | 0.68 | 0.46–1.02 | 0.061 |
| Arterial hypertension | 0.72 | 0.34–1.37 | 0.322 | 0.55 | 0.35–0.87 | 0.010 |
| Diabetes mellitus | 2.57 | 1.50–4.41 | 0.001 | 2.28 | 1.50–3.47 | < 0.0001 |
| Ever smoker | 0.66 | 0.38–1.13 | 0.127 | 0.85 | 0.57–1.29 | 0.450 |
| Creatinine on admission | 2.63 | 1.83–3.78 | < 0.0001 | 2.84 | 2.15–3.76 | < 0.0001 |
| DNase 1 SNP | 2.02 | 1.01–4.01 | 0.046 | 2.01 | 1.91–3.39 | 0.009 |
Multivariable Cox regression was used to assess the influence of a homozygous SNP in the Q222R DNase 1 gene on cardiovascular and all-cause mortality, after a median follow-up of 60.0 [IQR 30.3, 91.5] months
BMI body mass index, CI confidence interval, DNase deoxyribonuclease, HR hazard ratio, IQR interquartile range, SNP single nucleotide polymorphism, STEMI ST-segment elevation myocardial infarction